Feature | February 28, 2013

Medtronic Gains European Approval for Engager Transcatheter Valve

New Valve Provides Transapical Option for Physicians Treating Patients with Aortic Stenosis

Engager TAVI valve

 

February 28, 2013 — Medtronic Inc. announced European CE (Conformité Européenne) mark approval for its Engager Transcatheter Aortic Valve Implantation (TAVI) System with transapical delivery catheter. The system is indicated to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR).

The new valve demonstrated positive clinical outcomes in its European Pivotal Trial. Results from the multi-center trial, which were presented during late-breaking trial sessions at the recent European Association for Cardio-Thoracic Surgery and the Society of Thoracic Surgeons annual meetings, revealed high rates of procedural success, minimal paravalvular leak (PVL) and continuing clinical benefits for patients over time.

In the trial, the Engager valve was delivered transapically and had 94.3 percent overall device success (according to Valve Academic Research Consortium modified definitions). There were no procedures requiring a second valve and no occurrences of valve embolization, coronary obstruction or device malposition. No patients had moderate or severe PVL at six months, as measured by an independent echocardiography core lab. In addition, while most patients (88 percent) were NYHA Class III or IV at baseline, at six months 82 percent of patients had improved to NYHA Class I or II.

“The Engager valve has demonstrated exceptional clinical results, and by adding it to our transcatheter valve portfolio, we are providing heart teams with more options for achieving the best outcomes for every patient with severe aortic stenosis,” said John Liddicoat, M.D., senior vice president of Medtronic and president of the Medtronic structural heart business.

The Medtronic Engager System is not available in the United States.

The Engager valve uses a minimally?invasive delivery system via a catheter inserted in the apex (the lower, pointed end) of the heart. The valve is comprised of bovine tissue leaflets and a self?expanding nitinol frame designed to promote annular sealing to minimize paravalvular leak. Control arms simplify implantation, and the supra-annular valve positioning facilitates leaflet coaptation (connections) in non-circular anatomy for optimal hemodynamic performance. A direct aortic delivery system for Engager will be introduced in the future.

For more information: www.medtronic.com

 

Related Content

Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device
News | Heart Valve Technology| April 20, 2017
The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center...
Updated AATS Guidelines Help Cardiovascular Surgeons Navigate Challenges of Managing Ischemic Mitral Regurgitation
News | Heart Valve Technology| April 20, 2017
April 20, 2017 — Mitral regurgitation can occur in up to 50 percent of patients with ischemic heart disease and even
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT)| April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
PinnacleHealth Initiates Clinical Study of TriGuard Embolic Protection Device
News | Embolic Protection Devices| April 11, 2017
Through a new clinical trial, patients at Harrisburg, Pa.-based PinnacleHealth have access to an investigational device...
Boston Scientific is buying TAVI valve maker Symetis, which has European approval for its Acurate Neo valve

The Symetis Acurate Neo TAVI valve.

News | Heart Valve Technology| April 11, 2017
April 10, 2017 — Boston Scientific recently announced a $435 million cash deal to acquire Symetis SA, a privately-hel
SCAI, MEDCAC panel, health outcomes, heart failure, treatment technologies
News | Heart Failure| April 04, 2017
This week the Centers for Medicare & Medicaid Services (CMS) convened a panel of the Medicare Evidence Development...
CardioMEMS, heart failure, PA pressure monitoring, ACC17
News | March 30, 2017
March 30, 2017 — New late-breaking featured clinical research presented today adds strong clinical support for Abbott
Sponsored Content | Videos | Heart Valve Technology| March 24, 2017
Michael Reardon, M.D., professor of cardiothoracic surgery at Houston Methodist DeBakey Heart and Vascular Center, di
microbleeds, brain bleeds caused by TAVR

An MRI brain scan showing multiple microbleeds in a transcatheter aortic valve replacement (TAVR) patient from the study.

Feature | Heart Valve Technology| March 23, 2017
March 22, 2017 — A quarter of the patients in a single-center study of 84 patients undergoing transcatheter aortic va
Cardiogard embolic protection system for surgical valve reaplacement

The CardioGard embolic protection system for surgical aortic valve replacement.

Feature | Embolic Protection Devices| March 22, 2017
March 22, 2017 — Two U.S.
Overlay Init